News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
Mesothelioma Blog
Latest News
- Libby Clinic Busy with Mesothelioma Screenings
- American Workers Still Exposed to Mesothelioma-Causing Asbestos
- Mesothelioma Patient Featured on ABC’s BostonMed
- Stand Up 2 Cancer Telethon Scheduled for September 10th – Tune In to Join the Cause to Raise Funds for Mesothelioma and Other Cancers
- All Forms of Asbestos Shown to Cause Mesothelioma
- Mesothelin Finding Could Lead to Early Detection of Mesothelioma
- New York Attorney Calls for International Ban on Mesothelioma-Causing Asbestos
- Protein Can be Reliable for Diagnosing Malignant Mesothelioma
- Biomarker Successes Remain Elusive For Mesothelioma and Cancer Researchers
- Avastin May Not be Effective for Breast Cancer, But is Still an Option for Mesothelioma
News Archives
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
Tuesday, January 6, 2009
Source: Post-Bulletin
The Minnesota Post-Bulletin is running an article on the Minnesota Partnership for Biotechnology and Medical Genomics, a research partnership comprised of the Mayo Clinic, the University of Minnesota, and the State of Minnesota. The Partnership’s goal is to position Minnesota as a leader in medical research by developing innovative diagnostic and treatment strategies using the latest discoveries in biotechnology and genomics research.
The Partnership is currently involved with a number of important research projects, one of which is exploring the use of virotherapy in the treatment of malignant mesothelioma. Virotherapy is a cutting-edge cancer treatment protocol that uses genetically-modified viruses to target cancerous cells, while leaving healthy ones alone. It is still in the experimental stages, but if successful, virotherapy could lead to more effective and better targeted treatments than many of the current therapeutic modalities. The particular virotherapy project the Partnership has funded is studying the use of an adapted measles virus to deliver mesothelioma treatments. The study is led by Robert Krattzke, M.D., of the University of Minnesota, and Stephen Russell, M.D., Ph.D., of the Mayo clinic, the institution where the measles virus under investigation was developed at.
Labels: mesothelioma, treatments
posted by Joseph DiCastro at 3:52 PM
